Please ensure Javascript is enabled for purposes of website accessibility

Better Buy: Pfizer Inc. vs. Johnson & Johnson

By Keith Speights - Dec 1, 2017 at 8:42AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

One of these pharma giants clearly wins in two out of three key criteria for investors.

With only one month remaining in 2017, it's pretty clear which big pharma stock has been the better pick this year between Pfizer (PFE 2.15%) and Johnson & Johnson (JNJ 0.09%). J&J's share price is up more than 20%, while Pfizer stock is only up a little over half as much.

Investing is kind of like driving, though. It's much more important to look ahead than it is to focus on what's in the rearview mirror. Which of these stocks is the better choice for investors in the years to come? Here's how Pfizer and Johnson & Johnson compare in three key categories.

Man facing wall with line showing point A and point B

Image source: Getty Images.


Several factors drive growth for pharmaceutical companies. Obviously, the prospects for current products already on the market are very important. The companies' pipelines also play a critical role in determining how much growth could be attained. And the ability to make acquisitions and licensing deals is another key determinant.

The easiest of these factors to use in comparing Pfizer and J&J are current products. For Pfizer, there's good and bad news. The company's innovative health segment grew revenue by nearly 11% year, led by blockbuster drugs Eliquis, Ibrance, and Lyrica. However, Pfizer's essential health segment is dragging down overall revenue growth due to falling sales for drugs that have lost exclusivity. 

Johnson & Johnson has its own challenges, with sales for its top-selling drug Remicade declining due to biosimilar competition (including Pfizer's Inflectra). J&J's consumer segment also has sluggish sales growth. Overall, though, J&J's revenue growth is stronger than Pfizer's has been this year, thanks in large part from acquisitions.

Both companies have solid pipelines. Pfizer awaits regulatory approval for 10 drugs (some of which are for new indications for drugs already approved). The company also has 28 late-stage programs. J&J has even more programs in late-stage studies and is waiting on U.S. regulatory approval for eight drugs (including new indications). Earlier this year, research firm EvaluatePharma ranked J&J's pipeline as the fifth-best among big pharma companies, while Pfizer didn't make the top five list.

Acquisitions have been important to both companies. Pfizer bought Anacor and Medivation last year, while J&J acquired Actelion in 2017. Both companies are also likely to spur more growth through additional acquisitions. As of Oct. 1, 2017, Pfizer had cash, cash equivalents, and short-term investments totaling $16.9 billion, while J&J had $16.2 billion.

Which company has the overall advantage when it comes to growth prospects? My view is that Johnson & Johnson wins in this category.


It's a different story with income, though. J&J certainly has the more impressive track record. The healthcare giant has increased its dividend for 55 consecutive years. Pfizer has a nice streak of dividend hikes going now, but the economic crisis of 2008-2009 caused the big drugmaker to cut its dividend.

However, Pfizer's dividend yield of nearly 3.6% is much higher than J&J's yield of close to 2.4%. While J&J has been increasing its dividend at a slightly faster rate than Pfizer has in recent years, I don't see it catching up with Pfizer. In my opinion, Pfizer has the clear advantage in generating steady income for shareholders.


Pfizer stock currently trades at a little over 13 times expected earnings. That's significantly below J&J's forward earnings multiple of nearly 18. For investors who prefer using valuation metrics based on enterprise value, Pfizer also looks less expensive than J&J.

But what about factoring in growth prospects? Although the price-to-earnings-to-growth (PEG) ratio is usually used more for high-growth stocks, we can use it to compare the valuations of these two big pharma companies. Again, Pfizer has the edge, with a PEG ratio of 2.34 versus 2.73 for J&J. I view Pfizer as the better bargain between these two stocks.

Better buy

Pfizer has the advantage over Johnson & Johnson in two out of three categories. It's clearly the less expensive of the two stocks. And Pfizer claims the more attractive dividend, despite J&J's great history of dividend increases.

But do J&J's growth prospects make it the better pick? Not in my view. I look for Pfizer to make a few more acquisitions that will improve its growth potential. In the meantime, the company offers tremendous dividend yields. For me, Pfizer gets the slight nod, but both of these stocks are great picks for investors looking to win over the long run. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
$52.75 (2.15%) $1.11
Johnson & Johnson Stock Quote
Johnson & Johnson
$178.30 (0.09%) $0.16

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.